This site contains promotional information intended only for healthcare professionals resident in the United Kingdom

Visit Pfizer Medical site

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias

Menu

Close

Sign InLog Out
  • EN
Single LinkDropdownLabelLinkLinkLinkLinkLinked DropdownLabelLinkLinkLinkLinkMega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
Linked Mega MenuHeading

Example of description text sitting alongside header

LabelLinkLinkLinkLinkLabelLinkLinkLinkLinkLabelLinkLinkLinkLink
EN - EnglishSelect a languageLanguagesEN - EnglishFR - Françias
Search

Menu

Close

Sign In or RegisterLog Out
Pfizer MedicinesTherapy AreasExplore ContentEventsVideosMaterialsFeatured ArticlesLet’s ConnectSupplyAlliance HealthcareOff-contract claims

Adverse event reporting can be found at the bottom of the page

Menu

Close

EfficacyEfficacyEfficacyKey HighlightsHospitalisation DataSafetySafetySafetyAdverse Event Management: VOD/SOSKey PrecautionsDosingDosingDosingAdministrationSupport and ResourcesSupport and ResourcesVideosMaterialsPatient SupportKing's College Hospital: VOD Models of CareDr Castleton: Frontline approaches to B-cell ALL Dr Castleton: Management of relapsed disease in adult ALLDr Nicholson: Treatment landscape in R/R B-cell ALLDr Nicholson: Q&AMRD PubExplainer videoINO-VATE PubExplainer video

The content of this website has been produced in line with the BESPONSA® (inotuzumab ozogamicin) Summary of Product Characteristics for Great Britain and is intended for Healthcare Professionals based in Great Britain. BESPONSA Prescribing Information for Great Britain click here. BESPONSA Prescribing Information for Northern Ireland click here. Adverse event reporting information can be found at the bottom of the page.

King's College Hospital:
A dedicated ward round to assess and diagnose VOD

Collaborators: Michelle Kenyon, Consultant Nurse (BMT) & Dr Daniele Avenoso, Consultant Haematologist from Kings College Hospital NHS Foundation Trust

'a prompt diagnosis (of VOD) and having a system of surveillance are the key for success for patients before transplant or during the transplant procedure.'- Dr Daniele Avenoso, Consultant HaematologistAddressing an area of service development

Log in/register to watch Michelle Kenyon and Dr Daniele Avenoso from King's College Hospital NHS Foundation Trust discuss a new model of care which is a standardised and systematic approach to the screening, assessment and diagnosis of veno-occlusive disease (VOD).
 

Log in to learn moreLoading
King's College Hospital: A dedicated ward round to assess and diagnose VOD
Duration: 7 minutes 48 seconds

Watch Michelle Kenyon and Dr Daniele Avenso from King's College Hospital NHS Foundation Trust discuss a new model of care which is a standardised and systematic approach to the screening, assessment and diagnosis of veno-occlusive disease (VOD).

Get to know the contributors

Michelle Kenyon is a Consultant Nurse in haematopoietic stem cell transplantation, whose interests focus on improving the patient and caregiver experience during haematopoietic stem cell transplantation and supporting patients throughout their post-transplant recovery. Her research and service development interests centre on patient experience, psychosocial issues, treatment consequences and the unmet needs of those living with and beyond their diagnosis. Her role also enables her to lead a team and teach regularly. As current President of the European Blood and Marrow Transplant (EBMT) Nurses’ Group, she has a strong commitment to delivering education for nurses both nationally and internationally to benefit patient care. Michelle has authored two patient information books, which are used as the basis for informed consent for transplant recipients throughout the UK, and she is Co-editor of the first EBMT Textbook for Nurses, the second edition of which was published in 2023.

Dr Daniele Avenoso is a consultant haematologist in stem cell transplantation at King’s College Hospital. After his medical degree in Genoa (Italy) in 2011 at University of Genoa, he started his specialty training in haematology at the same University and obtained his CCT in 2017. He spent a year of his specialty training at Hammersmith Hospital in London (UK). Since 2017 he worked as stem cell transplant consultant in Italy, and he moved to King’s College Hospital in 2019 accepting a consultant position in BMT and ambulatory care. In 2020 he obtained his PhD in translation haematology (research project in miRNA and MDS). He is a member of the ALWP and CMWP of the EBMT and is interested in clinical trials in transplantation. His research area focuses on GVHD, alternative donors and new conditioning regimens.

VOD, veno-occlusive disease

PP-INO-GBR-0918. February 2024

This material is intended for UK healthcare professionals only and has been developed and funded by Pfizer in collaboration with Michelle Kenyon, Consultant Nurse and Dr Daniele Avenoso, Consultant Haematologist, from King's College Hospital.

Download an infographic summary

Download an infographic summary outlining how King's College Hospital successfully implemented a dedicated ward round to assess and diagnose VOD. 
 

DownloadLoading

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search 

for MHRA Yellow Card in Google Play or Apple App Store

 

Adverse events should also be reported to Pfizer Medical Information on 01304 616161

PfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign In or RegisterAccountSign Out

This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc

 

This website is brought to you by Pfizer Limited, a company registered in England 

and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ

 

Copyright © 2024 Pfizer Limited. All rights reserved.

 

VAT registration number GB201048427

PP-UNP-GBR-7866. January 2024
For UK Healthcare Professionals*

These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.

I confirm that I am a healthcare professional* resident in the United Kingdom.

If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.

*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.

PP-UNP-GBR-7812. January 2024

YesNo
You are now leaving PfizerPro​​​​​

​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned or controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site.​​​​​​​​​​​​​​

​​​​​​​PP-PFE-GBR-3858. November 2021​​​​​​​
​​​​​​​
You are now leaving PfizerPro
​​​​​​​
​​​​​​​You are now leaving www.pfizerpro.co.uk. Links to external websites are provided as a resource to the viewer. This website is neither owned nor controlled by Pfizer Ltd. 

Pfizer accepts no responsibility for the content or services of the linked site other than the information or other materials relating to ​​​​​Pfizer medicines or 
business which it has provided or reviewed.

PP-PFE-GBR-3859. November 2021
​​​​​​​